These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7648838)

  • 21. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.
    Pérez-Vázquez M; Román F; Varela MC; Cantón R; Campos J
    J Antimicrob Chemother; 2003 Jan; 51(1):147-51. PubMed ID: 12493800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.
    Sader HS; Erwin ME; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):372-81. PubMed ID: 1327789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
    Johnson DM; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):87-91. PubMed ID: 10091031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of Haemophilus influenzae with low susceptibility to quinolones and persistence in tosufloxacin treatment.
    Tanaka E; Hara N; Wajima T; Ochiai S; Seyama S; Shirai A; Shibata M; Shiro H; Natsume Y; Noguchi N
    J Glob Antimicrob Resist; 2019 Sep; 18():104-108. PubMed ID: 30753907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae.
    Bolmstrom A; Karlsson A
    Diagn Microbiol Infect Dis; 2002 Jan; 42(1):65-9. PubMed ID: 11821174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests.
    Barry AL; Fuchs PC; Jorgensen JH; Tenover FC; Allen SD; Hardy DJ; McLaughlin JC
    J Clin Microbiol; 1993 Mar; 31(3):751-3. PubMed ID: 8384632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
    Anderegg TR; Biedenbach DJ; Jones RN;
    Diagn Microbiol Infect Dis; 2003 Jun; 46(2):147-50. PubMed ID: 12812719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.
    Jones RN
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):167-70. PubMed ID: 7874885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.
    Barry AL; Thornsberry C; Gavan TL
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):544-9. PubMed ID: 2548865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
    Rittenhouse S; McCloskey L; Broskey J; Niconovich N; Jakielaszek C; Poupard J; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains.
    Biedenbach DJ; Jones RN;
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):225-8. PubMed ID: 11777665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
    Kronvall G; Holst E
    Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of PD 131628, a new quinolone antimicrobial agent.
    Cooper MA; Andrews JM; Wise R
    J Antimicrob Chemother; 1992 May; 29(5):519-27. PubMed ID: 1320603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
    Crokaert F; Aoun M; Duchateau V; Grenier P; Vandermies A; Klastersky J
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):696-8. PubMed ID: 8894585
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.